Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gancotamab - Merrimack Pharmaceuticals

Next Previous
X
Search
Drug Profile

Gancotamab - Merrimack Pharmaceuticals

Alternative Names: Nano-doxorubicin

Latest Information Update: 10 Apr 2017

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HERMES BioSciences
  • Developer Merrimack Pharmaceuticals
  • Class Antineoplastics; Doxorubicins; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA intercalators; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Breast cancer

Highest Development Phases

  • Discontinued HER2 positive breast cancer

Most Recent Events

  • 01 Mar 2017 Discontinued - Phase-II for Her2-positive-breast-cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Austria, Canada, France, Germany, Spain, Belgium, Italy, USA (IV) (Merrimack Pharmaceuticals 10-K, March 2017)
  • 08 Jan 2017 MM 302 is available for licensing as of 08 Jan 2017. www.merrimack.com
  • 21 Dec 2016 Merrimack Pharmaceuticals terminates the phase II HERMIONE trial in Her2-positive-breast-cancer due to the inability of MM 302 to demonstrate benefit over the comparator treatments

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top